Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06260969
Other study ID # TJHH-2023-WM13
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2022
Est. completion date September 30, 2025

Study information

Verified date February 2024
Source Tianjin Huanhu Hospital
Contact Ming Wei, PhD
Phone 13502182903
Email drweiming@163.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The study is a prospective multicentre registry study. Patients admitted to 10 stroke centres nationwide from September 2022 to September 2025 with acute ischaemic stroke due to large vessel occlusion considering underlying ICAS and treated with emergency endovascular thrombolysis were included for analysis. Patients who met the general inclusion criteria underwent thrombectomy and the necessary remedial treatment.


Description:

The focus of this trial is to investigate the neuroprotective effects of endovascular hypothermia on the refractory disease of large vessel occlusion with underlying ICAS by performing different modes of endovascular interventions including stenting, balloon dilationand balloon dilation combined with stenting in patients who meet clinical and imaging criteria. The clinical prognosis of patients with different treatment modalities will be followed up to provide high quality clinical evidence to guide the interventional treatment of potential large vessel occlusions in ICAS. The main objectives of the study were to establish a prospective cohort of acute large vessel occlusions with potential ICAS treated with endovascular therapy based on the specific etiology of stroke with a high prevalence of intracranial atherosclerotic stenosis in the Chinese population; to explore the efficacy and safety of endovascular therapy for acute ischaemic stroke with potential ICAS; to investigate the use of different endovascular treatment modalities for acute ischaemic stroke with potential ICAS in the Chinese population; and to explore the neuroprotective effects of selective endovascular hypothermia on large vessel occlusions with potential ICAS. To explore the neuroprotective effect of selective endovascular hypothermia on large vessel occlusion in potential ICAS. To provide objective data and theoretical support for the choice of treatment for large vessel occlusion in underlying ICAS


Recruitment information / eligibility

Status Recruiting
Enrollment 470
Est. completion date September 30, 2025
Est. primary completion date September 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - CT scan to exclude intracranial haemorrhage;CT angiography (CTA), magnetic resonance angiography (MRA) or digital subtraction angiography showing occlusion of the distal intracranial carotid artery or the first segment of the middle cerebral artery;ELVO with a base ICAS of > 70%;Mechanical thrombectomy within 6h after symptom onset in ischemic stroke;NIHSS=6;receiving endovascular treatments;informed consent form signed by the patient or their legal representatives. Exclusion Criteria: - Hemorrhagic body, coagulation factor deficiency or oral anticoagulant therapy(INR > 3.0);Baseline platelet count <50,000/µL;Baseline blood glucose <50mg/dL or >400mg/dL;Intractable hypertension(systolic blood pressure >220 mmHg or diastolic blood pressure >110 mmHg) that cannot be controlled by medication;Patients intubated without a NIHSS score assessed by a neurologist or emergency physician prior to intubation;Stroke attack with epilepsy affecting baseline NIHSS score;End-stage diseases leading to less than one year of expected survival for patients;Severe allergy to contrast media;Patients with renal insufficiency (blood creatinine = 3 mg/dL);Female patients who are pregnant or breastfeeding;The patient is participating in other drugs or device studies that may affect this study;Patient with cerebral vasculitis

Study Design


Intervention

Device:
balloon dilatation
Direct balloon dilation vs stenting vs embolectomy + tirofiban vs embolectomy + balloon dilation vs embolectomy + balloon dilation + intracranial stenting

Locations

Country Name City State
China Tianjin Huanhu Hospital Tianjin Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Tianjin Huanhu Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients achieving a clinical prognosis of mRS 0-2 at 90 days Proportion of patients achieving a clinical prognosis of mRS 0-2 at 90 days patients achieve a clinical prognosis of mRS 0-2 at 90 days
Secondary Proportion of patients with a good prognosis early after treatment Decrease in NIHSS score = 8 or NIHSS score of 0-2 in 24 (-2/+12) hours 24 hours after thrombectomy
Secondary Change in final cerebral infarct volume relative to baseline at 24 (-2/+12) hours postoperatively on CT/MR Change in final cerebral infarct volume relative to baseline at 24 (-2/+12) hours postoperatively on CT/MR 24 hours after thrombectomy
Secondary Vascular recanalization Revascularisation assessed by DSA immediately after thrombectomy;Postoperative revascularisation assessed by CTA/MRA/DSA using Arterial Occlusive Lesion (AOL) grading at 24 (-2/+12) hours postoperatively;Application of bedside TCD for assessment of revascularisation Immediately after thrombectomy
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT06437431 - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy Phase 2/Phase 3
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3